

## Rubraca<sup>®</sup> (rucaparib) – Indication update

- On December 21, 2022, the [FDA approved](#) an update to the [Rubraca \(rucaparib\)](#) drug label, restricting the maintenance treatment of recurrent ovarian cancer indication to only the patient population with a deleterious *BRCA* mutation (germline and/or somatic).
- Rubraca is also approved for the treatment of adult patients with a deleterious *BRCA* mutation (germline and/or somatic)- associated metastatic castration-resistant prostate cancer who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy.
- Patients should be selected for the maintenance treatment of recurrent ovarian cancer with Rubraca based on the presence of a deleterious *BRCA* mutation (germline and/or somatic).
- An FDA-approved test for the detection of deleterious germline and/or somatic *BRCA* mutations is not currently available.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews<sup>®</sup> is published by the Optum Rx Clinical Services Department.